Roche

News

NICE backs Ocrevus for PPMS in England - but with caveats

Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevu

News

NICE recommends Roche's Tecentriq combo for certain lung can...

Certain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made a draft recommendation that the NHS should fund Roche’s cocktail i

News

Nimble Therapeutics spins out of Roche to focus on peptide R...

US biotech Nimble Therapeutics has announced it is operating as a standalone business after spinning out from Roche, focusing on drug R&D based around peptides.

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

Views & Analysis

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g

News

Roche insists Spark deal is still on, despite lacklustre tak...

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension to the tender process.

NICE backs Ocrevus for PPMS in England - but with caveats

NICE recommends Roche's Tecentriq combo for certain lung can...

Nimble Therapeutics spins out of Roche to focus on peptide R...

Sandoz strikes deal with EirGenix for Herceptin biosimilar

R&D Roundup: Pharma gets in on the biotech boom

Roche insists Spark deal is still on, despite lacklustre tak...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks